Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

21.70 -0.57 (-2.54%)

Streaming Delayed Price Updated: 1:45 PM EST, Dec 8, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

33 34 Next >

12 Analysts Have This To Say About Sarepta Therapeutics ↗

May 20, 2024

Via Benzinga

3 Biotech Stocks With the Potential to Make You an Overnight Millionaire ↗

May 04, 2024

Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments.

Via InvestorPlace

Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health

May 03, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

What Analysts Are Saying About Sarepta Therapeutics Stock ↗

May 02, 2024

Via Benzinga

Apple, Kellanova And 3 Stocks To Watch Heading Into Thursday ↗

May 02, 2024

Via Benzinga

Sarepta Therapeutics: Q4 Earnings Insights ↗

February 28, 2024

Via Benzinga

A Preview Of Sarepta Therapeutics's Earnings ↗

February 27, 2024

Via Benzinga

SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 01, 2024

SRPT stock results show that Sarepta Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript ↗

May 01, 2024

SRPT earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments

May 01, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

1 Top Growth Stock to Buy and Hold for 10 Years ↗

May 01, 2024

This company's lineup might look very different in a decade, but the end result will be the same for investors.

Via The Motley Fool

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 30, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Stock Shows Improved Technical Strength ↗

April 29, 2024

The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73.

Via Investor's Business Daily

Sarepta Therapeutics to Announce First Quarter 2024 Financial Results

April 24, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst ↗

April 08, 2024

Sarepta stock has taken a beating this year, and it might not be over with the first-quarter report looming.

Via Investor's Business Daily

2 Biotech Stocks to Buy Hand Over Fist in April ↗

April 06, 2024

These drugmakers have made important moves over the past year.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

April 04, 2024

Via Benzinga

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 29, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback ↗

March 28, 2024

The company could follow Sarepta Therapeutics with a gene therapy for Duchenne muscular dystrophy.

Via Investor's Business Daily

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? ↗

March 13, 2024

The threat is still emerging, but it could be significant.

Via The Motley Fool

This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO ↗

March 08, 2024

REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients.

Via Benzinga

Got $1,000? Buy These Hot Growth Stocks Before They Take Off. ↗

March 08, 2024

These stocks haven't been able to get much traction lately, even though they clearly deserve to now.

Via The Motley Fool

Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst ↗

March 04, 2024

The upcoming regulatory decision on its latest drug could be big.

Via The Motley Fool

Sarepta Therapeutics to Present at Upcoming Investor Conferences

March 04, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 29, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program

February 29, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript ↗

February 29, 2024

SRPT earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments

February 28, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Is It Too Late to Buy Sarepta Therapeutics Stock? ↗

February 28, 2024

The company's hyperfocus on its core area could continue to be highly lucrative.

Via The Motley Fool

Earnings Scheduled For February 28, 2024 ↗

February 28, 2024

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.

Via Benzinga

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.